论文部分内容阅读
本研究的目的是观察严重急性呼吸综合征 (severeacuterespiratorysyndrome ,SARS)患者抗SARS 冠状病毒 (SARS CoV)抗体IgG和IgM的产生及抗体效价变化特征 ,探索采集SARS痊愈患者抗血清的时机。应用ELISA方法对随机抽取的 156名SARS患者血清标本进行抗SARS CoV抗体IgG和IgM抗体效价测定。结果表明 ,156名SARS患者于病后 3至 9周期间 ,IgG抗体阳性率为 75.6% ,IgM抗体阳性率为 41.7% ,IgG和IgM抗体均阳性为 41% ,IgG和IgM抗体均阴性为 2 3 .7% ;IgG抗体阳性患者中抗体效价为 18.2 3± 2 4.72 ,IgM抗体阴性患者抗体效价为 2 .18± 1.13 ;IgG和IgM抗体效价与SARS患者的性别、年龄、病程、体温正常天数无显著相关性。结论 :并非所有SARS患者都能产生抗SARS CoV抗体 ,即使产生抗体 ,其效价的个体差异也较大 ,并不能通过性别、年龄、病程及体温正常天数等因素较准确地评估抗体的效价。因此 ,在SARS抗血清采集前 ,应重新进行抗体效价测定 ,遴选具有高效价抗SARS CoV抗体的SARS痊愈患者进行抗血清的采集 ,才能提高所采集的抗血清在临床的治疗效果 ,同时又可为患者抗体输注提供量化指标
The objective of this study was to investigate the production of anti-SARS coronavirus (SARS CoV) IgG and IgM antibodies and their antibody titer in patients with severe acute respiratory syndrome (SARS) and to explore the timing of anti-SARS coronavirus recovery in patients with SARS. Serum samples from 156 randomly selected SARS patients were tested for anti-SARS CoV IgG and IgM antibody titer by ELISA. The results showed that among the 156 patients with SARS, the positive rate of IgG antibody was 75.6% and the positive rate of IgM antibody was 41.7% between 3 and 9 weeks after the illness, the positive rate of IgG and IgM antibody was 41%, and the IgG and IgM antibody was 2 The antibody titers in IgG-positive patients were 18.2 3 ± 2. 4.72, and the antibody titers in IgM negative patients were 2.18 ± 1.13. The IgG and IgM antibody titers were significantly correlated with the gender, age, course of disease, There was no significant correlation between the normal days of body temperature. CONCLUSIONS: Not all patients with SARS can develop anti-SARS CoV antibodies. Even if the antibody is produced, there is a large individual difference in potency. Therefore, the antibody titer can not be accurately evaluated by factors such as gender, age, duration of disease and normal body temperature . Therefore, prior to the collection of SARS antiserum, antibody titer should be re-determined, and the selection of anti-SARS patients with high titer anti-SARS CoV antibodies for antiserum should be used to improve the clinical efficacy of antisera collected. Can provide quantitative indicators for patient antibody infusion